As shown in Fig 6, a low concentration of ixazomib did not change the cleaved caspase-3 (Fig 6A and 6B) or procaspase-3 content (Fig 6A and 6C) in controls, after ischemia or after ischemia reperfusion; in contrast, ixazomib at 1 μM, increased both, the active caspase-3 content (Fig 6A and 6B) and the total procaspase-3 (Fig 6A and 6C) in hearts subjected to ischemia and in control hearts as well. Here, CASP3 is linked to ischemia.